Table 2. (a) Fifty-nine significantly enriched pathways in SAS; (b) Thirteen significantly enriched pathways in FaDu.
| KEGG pathway | Genes | P-value |
|---|---|---|
|
(a) SAS | ||
| Protein processing in endoplasmic reticulum |
30 |
4.67E–13 |
| Pathways in cancer |
40 |
1.75E–11 |
| Endocytosis |
29 |
1.90E–10 |
| Focal adhesion |
29 |
2.40E–10 |
| Small cell lung cancer |
19 |
4.29E–10 |
| Regulation of actin cytoskeleton |
29 |
7.09E–10 |
| Lysosome |
21 |
5.25E–09 |
| Axon guidance |
21 |
1.35E–08 |
| ECM–receptor interaction |
15 |
1.07E–06 |
| Insulin signalling pathway |
17 |
1.91E–05 |
| Amoebiasis |
14 |
6.64E–05 |
| p53 signalling pathway |
11 |
1.15E–04 |
| Valine, leucine and isoleucine degradation |
9 |
1.05E–04 |
| Vasopressin-regulated water reabsorption |
9 |
1.05E–04 |
| Prostate cancer |
12 |
2.55E–04 |
| Bacterial invasion of epithelial cells |
10 |
7.80E–04 |
| Notch signalling pathway |
8 |
9.55E–04 |
| ErbB signalling pathway |
11 |
9.49E–04 |
| Phagosome |
14 |
1.11E–03 |
| Cell cycle |
13 |
1.31E–03 |
| Glioma |
9 |
1.37E–03 |
| mTOR signalling pathway |
8 |
1.80E–03 |
| Tight junction |
13 |
1.99E–03 |
| HCM |
10 |
2.00E–03 |
| Pancreatic cancer |
9 |
2.61E–03 |
| Chronic myeloid leukaemia |
9 |
3.45E–03 |
| Dilated cardiomyopathy |
10 |
3.47E–03 |
| Prion diseases |
6 |
4.19E–03 |
| MAPK signalling pathway |
19 |
4.51E–03 |
| Melanogenesis |
10 |
6.69E–03 |
| Calcium signalling pathway |
14 |
8.25E–03 |
| Galactose metabolism |
5 |
8.43E–03 |
| Nucleotide excision repair |
6 |
9.87E–03 |
| Bladder cancer |
6 |
1.09E–02 |
| NOD-like receptor signalling pathway |
7 |
1.08E–02 |
| Inositol phosphate metabolism |
7 |
1.08E–02 |
| ARVC |
8 |
1.08E–02 |
| Glycosaminoglycan degradation |
4 |
1.33E–02 |
| Vascular smooth muscle contraction |
10 |
1.50E–02 |
| Ubiquitin-mediated proteolysis |
11 |
1.77E–02 |
| Amino sugar and nucleotide sugar metabolism |
6 |
1.80E–02 |
| SNARE interactions in vesicular transport |
5 |
2.10E–02 |
| RNA degradation |
7 |
2.09E–02 |
| Starch and sucrose metabolism |
6 |
2.28E–02 |
| Long-term potentiation |
7 |
2.36E–02 |
| Endometrial cancer |
6 |
2.40E–02 |
| CAMs |
10 |
2.55E–02 |
| Non-small cell lung cancer |
6 |
2.47E–02 |
| Vibrio cholerae infection |
6 |
2.47E–02 |
| Melanoma |
7 |
2.44E–02 |
| PPAR signalling pathway |
7 |
2.44E–02 |
| Adherens junction |
7 |
2.58E–02 |
| Oocyte meiosis |
9 |
2.91E–02 |
| Sphingolipid metabolism |
5 |
2.91E–02 |
| Fatty acid metabolism |
5 |
3.18E–02 |
| B-cell receptor signalling pathway |
7 |
3.22E–02 |
| Phosphatidylinositol signalling system |
7 |
3.39E–02 |
| Glycosphingolipid biosynthesis – ganglio series |
3 |
3.60E–02 |
| Protein digestion and absorption |
7 |
3.75E–02 |
|
(b) FaDu | ||
| Protein processing in endoplasmic reticulum |
17 |
4.67E–07 |
| Systemic lupus erythematosus |
13 |
3.33E–07 |
| Pathways in cancer |
17 |
3.24E–03 |
| Lysosome |
9 |
1.11E–02 |
| Endocytosis |
11 |
1.94E–02 |
| Valine, leucine and isoleucine degradation |
5 |
2.65E–02 |
| Cell cycle |
8 |
3.32E–02 |
| Bile secretion |
6 |
3.03E–02 |
| Neurotrophin signalling pathway |
8 |
2.72E–02 |
| Insulin signalling pathway |
8 |
3.80E–02 |
| Ubiquitin-mediated proteolysis |
8 |
3.79E–02 |
| Inositol phosphate metabolism |
5 |
4.26E–02 |
| Oocyte meiosis | 7 | 3.97E–02 |
Abbreviations: ARVC=arrhythmogenic right ventricular cardiomyopathy; CAMs=cell adhesion molecules; ECM=extracellular matrix; HCM=hypertrophic cardiomyopathy; KEGG=Kyoto Encyclopedia of Genes and Genomes; MAPK= mitogen-activated protein kinase; mTOR= mammalian target of rapamycin; NOD=nucleotide-binding oligomerization domain; PPAR=peroxisome proliferator-activated receptor; SNARE=soluble NSF attachment protein receptor..